EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors

Kathryn L Eschbacher iD, Quynh T Tran, Evgeny A Moskalev, Sarah Jenkins, Karen Fritchie, Robert Stoehr, Alissa Caron, Michael J Link, Paul D Brown, Andrew Guajardo, Daniel J Brat, Ashley Wu und 17 weitere

Brain Pathology · 2024-11 · 34 (6)

DOI: 10.1111/bpa.13256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 24.03.2024. Verfasst von Kathryn L Eschbacher und 28 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa Hospitals & Clinics IA, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Solitary Fibrous Tumors, DNA Methylation, STAT6 Transcription Factor, Repressor Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling ( n = 80) and targeted TERT promoter mutation testing ( n = 98). Associations were examined with NAB2::STAT6 fusion status ( n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) ( p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade ( p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 ( n = 38), Cluster 2 ( n = 22), and Cluster 3 ( n = 20). Methylation clusters were significantly associated with fusion type ( p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS ( p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Solitary Fibrous TumorsDNA MethylationSTAT6 Transcription FactorRepressor ProteinsMeningeal NeoplasmsHumansFemaleMaleMiddle AgedAdultAgedYoung AdultAdolescentAged, 80 and overChildPrognosisTelomerase

Stichwörter der Autor:innen

CNS WHO gradeNAB2::STAT6TERTmeningeal solitary fibrous tumorsolitary fibrous tumor

Substanzen

STAT6 Transcription FactorRepressor ProteinsNAB2 protein, humanSTAT6 protein, humanTERT protein, humanTelomerase

Autor:innen und Institutionen

  • University of Iowa Hospitals & Clinics IA, Iowa City, Iowa, USA.
  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • University Hospital Erlangen, Erlangen, Germany.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Johns Hopkins, Baltimore, Maryland, USA.

ORCID-Profile: Kathryn L Eschbacher, David N Louis, Caterina Giannini

Förderung

  • NCI NIH HHS

Zitieren

APA

Eschbacher, K. L., Tran, Q. T., Moskalev, E. A., Jenkins, S., Fritchie, K., Stoehr, R., Caron, A., Link, M. J., Brown, P. D., Guajardo, A., Brat, D. J., Wu, A., Santagata, S., Louis, D. N., Brastianos, P. K., Kaplan, A. B., Alexander, B., Rossi, S., Ferrarese, F., …, & Giannini, C. (2024). NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors. Brain Pathology, 34(6). https://doi.org/10.1111/bpa.13256

Vancouver

Eschbacher KL, Tran QT, Moskalev EA, Jenkins S, Fritchie K, Stoehr R, et al. NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors. Brain Pathology. 2024;34(6). doi:10.1111/bpa.13256

BibTeX
@article{Eschbacher2024,
  author = {Eschbacher, Kathryn L and Tran, Quynh T and Moskalev, Evgeny A and Jenkins, Sarah and Fritchie, Karen and Stoehr, Robert and Caron, Alissa and Link, Michael J and Brown, Paul D and Guajardo, Andrew and Brat, Daniel J and Wu, Ashley and Santagata, Sandro and Louis, David N and Brastianos, Priscilla K and Kaplan, Alexander B and Alexander, Brian and Rossi, Sabrina and Ferrarese, Fabio and Raleigh, David R and Nguyen, Minh P and Gross, John and Velazquez Vega, Jose and Rodriguez, Fausto and Perry, Arie and Martinez-Lage, Maria and Orr, Brent A and Haller, Florian and Giannini, Caterina},
  title = {NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors},
  journal = {Brain Pathology},
  year = {2024},
  volume = {34},
  number = {6},
  doi = {10.1111/bpa.13256}
}
Kostenlos starten →